Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study

BACKGROUND: Rituximab occasionally induces reactivation of hepatitis B virus (HBV) in patients with resolved HBV, at times with fatal consequences. The optimal duration of prophylactic antiviral therapy in this situation is unclear. We aimed to investigate the difference in HBV reactivation accordin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Heejoon, Yu, Su Jong, Lee, Hong Ghi, Kim, Tae Min, Lee, Yun Bin, Cho, Eun Ju, Lee, Jeong-Hoon, Yoon, Jung-Hwan, Kim, Yoon Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353911/
https://www.ncbi.nlm.nih.gov/pubmed/37463687
http://dx.doi.org/10.3346/jkms.2023.38.e216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353911/
https://www.ncbi.nlm.nih.gov/pubmed/37463687
http://dx.doi.org/10.3346/jkms.2023.38.e216

Ejemplares similares